REPLIDYNE AND FOREST LABORATORIES ANNOUNCE FAROPENEM MEDOXOMIL LICENSING AGREEMENT
Replidyne, Inc., a privately held biopharmaceutical company and Forest Laboratories
Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. announced
today that the two companies have entered into an agreement for the commercialization,
development and distribution of Replidyne's new oral antibiotic, faropenem medoxomil,
in the United States.